144 related articles for article (PubMed ID: 1390279)
1. In vitro potency and selectivity of the non-steroidal androgen aromatase inhibitor CGS 16949A compared to steroidal inhibitors in the brain.
Wozniak A; Holman SD; Hutchison JB
J Steroid Biochem Mol Biol; 1992 Oct; 43(4):281-7. PubMed ID: 1390279
[TBL] [Abstract][Full Text] [Related]
2. Action of endogenous steroid inhibitors of brain aromatase relative to fadrozole.
Wozniak A; Hutchison JB
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):641-5. PubMed ID: 8476776
[TBL] [Abstract][Full Text] [Related]
3. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
Häusler A; Schenkel L; Krähenbühl C; Monnet G; Bhatnagar AS
J Steroid Biochem; 1989 Jul; 33(1):125-31. PubMed ID: 2527324
[TBL] [Abstract][Full Text] [Related]
4. Fadrozole: a potent and specific inhibitor of aromatase in the zebra finch brain.
Wade J; Schlinger BA; Hodges L; Arnold AP
Gen Comp Endocrinol; 1994 Apr; 94(1):53-61. PubMed ID: 8045368
[TBL] [Abstract][Full Text] [Related]
5. Reversible inhibition of human placental microsomal aromatase by CGS 18320B and other non-steroidal compounds.
Bullion KA; Osawa Y; Braun DG
Endocr Res; 1990; 16(2):255-67. PubMed ID: 2140551
[TBL] [Abstract][Full Text] [Related]
6. Effect of aromatase inhibitors on estrogen 2-hydroxylase in rat liver.
Purba HS; King EJ; Richert P; Bhatnagar AS
J Steroid Biochem Mol Biol; 1994 Feb; 48(2-3):215-9. PubMed ID: 8142297
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity studies of non-steroidal aromatase inhibitors: the crystal and molecular structures of CGS 16949A and CGS 18320B.
Van Roey P; Bullion KA; Osawa Y; Browne LJ; Bowman RM; Braun DG
J Enzyme Inhib; 1991; 5(2):119-32. PubMed ID: 1669441
[TBL] [Abstract][Full Text] [Related]
8. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
Tanaka M; Yano S; Hasegawa Y; Nakao K
Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
[TBL] [Abstract][Full Text] [Related]
10. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
[TBL] [Abstract][Full Text] [Related]
11. Two aromatase inhibitors inhibit the ability of a third to promote mating in male rats.
Yahr P
Horm Behav; 2015 Sep; 75():41-4. PubMed ID: 26232614
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
[TBL] [Abstract][Full Text] [Related]
13. Novel aromatase inhibitors.
Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
Yue W; Brodie AM
J Steroid Biochem Mol Biol; 1997; 63(4-6):317-28. PubMed ID: 9459198
[TBL] [Abstract][Full Text] [Related]
15. Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening.
Kitawaki J; Kim T; Kanno H; Noguchi T; Yamamoto T; Okada H
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):667-70. PubMed ID: 8476780
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
17. Effect of 1,4,6-androstatriene-3,17-dione (ATD), 4-hydroxy-4-androstene-3,17-dione (4-OH-A) and 4-acetoxy-4-androstene-3,17-dione (4-Ac-A) on the 5 alpha-reduction of androgens in the rat prostate.
Motta M; Zoppi S; Brodie AM; Martini L
J Steroid Biochem; 1986 Oct; 25(4):593-600. PubMed ID: 3773531
[TBL] [Abstract][Full Text] [Related]
18. A comparison of methods measuring aromatase activity in human placenta and rat ovary.
Purba HS; Bhatnagar AS
J Enzyme Inhib; 1990; 4(2):169-78. PubMed ID: 2151521
[TBL] [Abstract][Full Text] [Related]
19. Potency and specificity of CGS-16949A as an aromatase inhibitor.
Santen RJ; Langecker P; Santner SJ; Sikka S; Rajfer J; Swerdloff R
Endocr Res; 1990; 16(1):77-91. PubMed ID: 2139412
[TBL] [Abstract][Full Text] [Related]
20. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
Demers LM; Melby JC; Wilson TE; Lipton A; Harvey HA; Santen RJ
J Clin Endocrinol Metab; 1990 Apr; 70(4):1162-6. PubMed ID: 2156889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
